RAPIBLYK (R) is an ultra-short-acting, selective beta-1 adrenergic receptor blocker administered intravenously in a monitored hospital setting. Its pharmacological profile allows for rapid onset and ...

At 30 days, bleeding and pacemaker rates were lower than in TRISCEND II, but long-term outcomes are eagerly awaited.

AOP Health US, LLC today announced that the U.S. Food and Drug Administration (FDA) has approved RAPIBLYK (landiolol) for use in pediatric patients (from birth to This press release features ...

There are two types of inflammation: acute and chronic. Acute inflammation is the kind that lasts a few hours, days, or weeks, and it’s helpful to healing. It’s your immune system’s response when ...

Larissa Banitt is a registered nurse who combines her English and Nursing degrees in writing health content. She has worked on the floor on a medical-surgical unit and currently works providing care ...